WEI HU to Treatment Outcome
This is a "connection" page, showing publications WEI HU has written about Treatment Outcome.
Connection Strength
0.014
-
Randomised phase II study of docetaxel plus vandetanib versus docetaxel followed by vandetanib in patients with persistent or recurrent epithelial ovarian, fallopian tube or primary peritoneal carcinoma: SWOG S0904. Eur J Cancer. 2014 Jun; 50(9):1638-48.
Score: 0.007
-
Pegylated liposomal doxorubicin treatment in recurrent gynecologic cancer patients with renal dysfunction. Gynecol Oncol. 2007 Aug; 106(2):375-80.
Score: 0.004
-
Phase II study of carboplatin and liposomal doxorubicin in patients with recurrent squamous cell carcinoma of the cervix. Cancer. 2001 Nov 01; 92(9):2327-33.
Score: 0.003